This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Burtness B , Gibson M , Egleston B , Mehra R , Thomas L , Sipples R , Quintanilla M , Lacy J , Watkins S , Murren JR , Forastiere AA
Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer
Annals of Oncology. 2009 Jul;20(7) :1242-1248
PMID: ISI:000267440500015 PMCID: PMC2699385
AbstractMaterials and methods: Patients who had unresectable/metastatic squamous cell carcinoma or adenocarcinoma of the esophagus, measurable disease, Eastern Cooperative Oncology Group performance status of zero to two, and normal bilirubin were eligible. Tumor assessment was carried out every three cycles. Results: We enrolled 29 chemotherapy-naive (CN) and 15 chemotherapy-exposed (CE) eligible patients. Principal toxic effects were diarrhea, neutropenia, and hyperglycemia. There were no toxic deaths. There was one early death, from myocardial infarction. Among 26 CN and assessable patients, there were seven (26.9%) with a partial response (PR) and one (3.8%) with a complete response (CR). There were two PRs and one CR among the patients with CE disease. Median time to progression for CN patients was 4.0 months and for CE patients 3.5 months. Median survival for CN eligible patients was 9.0 months and for CE patients 11.4 months. Conclusions: Docetaxel-irinotecan combination given on a weekly x 2 of 3 schedule is promising in the treatment of advanced esophageal cancer.
NotesBurtness, B. Gibson, M. Egleston, B. Mehra, R. Thomas, L. Sipples, R. Quintanilla, M. Lacy, J. Watkins, S. Murren, J. R. Forastiere, A. A. 33 OXFORD UNIV PRESS; GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND 463OC